UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1467-1
Program Prior Authorization/Notification
Medication Danziten™ (nilotinib)
P&T Approval Date 1/2025
Effective Date 4/1/2025
1. Background:
Danziten™ (nilotinib) is a kinase inhibitor indicated for the treatment of adult patients with newly
diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic
phase, as well as treatment of adult patients with chronic phase (CP) and accelerated phase Ph+
CML resistant to or intolerant to prior therapy that included imatinib.1 The National Cancer
Comprehensive Network (NCCN) recommends the use of Danziten for primary or follow-up
CML therapy in all stages. NCCN also recommends Danziten for the treatment of Philadelphia
chromosome-positive B-cell acute lymphoblastic leukemia (B-ALL) as well as for the treatment
of soft tissue sarcoma of pigmented villonodular synovitis/tenosynovial giant cell tumor. 2
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of 19
years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or under
some circumstances. Some states also mandate usage of other Compendium references. Where such
mandates apply, they supersede language in the benefit document or in the notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Danziten will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Chronic Myeloid Leukemia
1. Initial Authorization
a. Danziten will be approved based on the following criterion:
(1) Diagnosis of chronic myeloid leukemia
Authorization will be issued for 12 months.
2. Reauthorization
© 2025 UnitedHealthcare Services, Inc.
1
a. Danziten will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Danziten therapy
Authorization will be issued for 12 months.
C. Acute Lymphoblastic Leukemia (Ph+B-ALL)
1. Initial Authorization
a. Danziten will be approved based on the following criterion:
(1) Diagnosis of Philadelphia chromosome-positive B-cell acute lymphoblastic
leukemia (Ph+ B-ALL)
Authorization will be issued for 12 months.
2. Reauthorization
a. Danziten will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Danziten therapy
Authorization will be issued for 12 months.
D. Soft Tissue Sarcoma
1. Initial Authorization
a. Danziten will be approved based on the following criterion:
(1) Diagnosis of pigmented villonodular synovitis/tenosynovial giant cell tumor
Authorization will be issued for 12 months.
2. Reauthorization
a. Danziten will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Danziten therapy
Authorization will be issued for 12 months.
E. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category
of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
2
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Danziten [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc.; November
2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed
December 3, 2024.
Program Prior Authorization/Notification - Danziten (nilotinib)
Change Control
1/2025 New program.
© 2025 UnitedHealthcare Services, Inc.
3